ER+/HER2+ breast cancer: are we really de-escalating?

Ann Oncol. 2019 Jun 1;30(6):875-877. doi: 10.1093/annonc/mdz130.

Authors

E de Azambuja¹, M Piccart-Gebhart²

Affiliations

¹ Department of Medical Oncology, Institut Jules Bordet and L'Université Libre de Bruxelles, Brussels, Belgium. Electronic address: evandro.azambuja@bordet.be.
² Department of Medicine, Institut Jules Bordet and L'Université Libre de Bruxelles, Brussels, Belgium.

PMID: 30993330
DOI: 10.1093/annonc/mdz130

No abstract available

Publication types

Editorial
Comment

MeSH terms

Breast Neoplasms*
Humans
Ki-67 Antigen
Letrozole
Neoadjuvant Therapy
Receptor, ErbB-2

Substances

Ki-67 Antigen
Letrozole
Receptor, ErbB-2